瑞雷治疗

最新新闻

• 评级变动
  Guggenheim Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $26
  \u5e02\u573a\u8d44\u8baf · 2026/5/26
• 评级变动
  CCORF Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• Citizens JMP Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $26
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Citizens JMP Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $21
  \u5e02\u573a\u8d44\u8baf · 2026/5/21
• 评级变动
  Goldman Sachs Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $31
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $20 to $27
  \u5e02\u573a\u8d44\u8baf · 2026/5/20
• 评级变动
  Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Oppenheimer Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• 评级变动
  A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $18 to $21
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $29
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  Analysts Are Bullish on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), Relay Therapeutics (RLAY)
  TipRanks · 2026/6/18
• J.P. Morgan Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $31
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $27
  \u5e02\u573a\u8d44\u8baf · 2026/5/21
• 评级变动
  H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $28
  \u5e02\u573a\u8d44\u8baf · 2026/5/26
• 评级变动
  J.P. Morgan Maintains Relay Therapeutics(RLAY.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  TD Cowen Maintains Relay Therapeutics(RLAY.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• JonesTrading Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  Goldman Sachs Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $22
  \u5e02\u573a\u8d44\u8baf · 2026/6/3
• 评级变动
  CCORF Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/8/21

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。